Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846468 · ClinicalTrials.gov registry record · Phase 1
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 205
- Enrollment target
NCT01846468 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 205 participants.
The verdict
NCT01846468, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 205 participants
- Enrollment target
Study Summary
The purpose of the study is to provide pertinent information to enable decisions regarding the developability of LHW090 for use in patients with chronic renal insufficiency, including a comparison of the potential risk-benefit ratio of several doses of the study drug to enable optimal doses to be tested in later studies.
Interventions
- DRUG Placebo
- DRUG LHW090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2013-03-01 |
| Est. Completion | 2014-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846468
The ClinicalTrials.gov registry entry for NCT01846468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01846468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01846468 about?
NCT01846468 is a clinical study titled "An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction". The purpose of the study is to provide pertinent information to enable decisions regarding the developability of LHW090 for use in patients with chronic renal insufficiency, including a comparison of the potential risk-benefit ratio of several doses of the study drug to enable optimal doses to be te...
What is the current status of trial NCT01846468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 205 participants. The study started on 2013-03-01. Estimated completion is 2014-06-28.
What interventions are being tested in trial NCT01846468?
The interventions under investigation include: Placebo (DRUG), LHW090 (DRUG).
Who is sponsoring clinical trial NCT01846468?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.